TAIWAN LIPOSOME COMPANY LTD

Business Nature: Manufacturer (Biopharmaceutical Company)

Company Introduction:

TAIWAN LIPOSOME COMPANY LTD (TLC) is a clinical-stage specialty pharmaceutical company headquartered in Taiwan. As a manufacturer, TLC is dedicated to the research, development, and production of novel nanomedicines. The company leverages its proprietary liposome-based drug delivery systems to enhance the safety and efficacy of existing drugs and to develop innovative therapies. TLC's primary focus areas include pain management, oncology, and ophthalmology, addressing significant unmet medical needs through its advanced technology platform. The company's mission is to develop and commercialize products that improve patient outcomes and quality of life globally.

TAIWAN LIPOSOME COMPANY LTD (TLC) manufactures or sells the following products: Ampholip Amphotericin B Liposome for Injection, TLC599 Dexycu Dexamethasone intravitreal implant, TLC590 ZILRETTA Triamcinolone acetonide extended-release injectable suspension, TLC399 VisiFane which is a drug candidate for Diabetic Macular Edema and wet Age-related Macular Degeneration, TLC177 which is a drug candidate for various cancers including rhabdomyosarcoma and Ewing sarcoma, and TLC199 which is a drug candidate for pulmonary diseases such as acute respiratory distress syndrome ARDS.